deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT02045797

Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

Sponsor: GlaxoSmithKline

Updated 9 times since 2017 Last updated: Oct 16, 2017 Started: Mar 24, 2014 Primary completion: Jun 29, 2015 Completion: Jun 29, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Infections, Bacterial, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 9 data snapshots since 2014. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshotCompleted~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshotCompleted~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshotCompleted~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

9 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2022 — Mar 2022 [monthly]

    Completed PHASE2

  5. Jan 2021 — Jan 2022 [monthly]

    Completed PHASE2

Show 4 earlier versions
  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  2. Oct 2017 — Jun 2018 [monthly]

    Completed PHASE2

  3. Feb 2017 — Oct 2017 [monthly]

    Completed PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .